B Vaxx/PD1 Vaxx - Imugene
Alternative Names: B-Vaxx/KEY-Vaxx vaccine - Imugene; B-Vaxx/PD1-Vaxx vaccine - Imugene; HER2/PD-1 vaccine - Imugene; PD-1 and HER2 cancer vaccine - ImugeneLatest Information Update: 28 Apr 2023
At a glance
- Originator Imugene
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists; ERBB-3 receptor antagonists; Immunostimulants; Programmed cell death 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Colorectal cancer